Rein Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Rein Therapeutics, Inc. (RNTX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.17 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-14
- Rein Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.72.
- Rein Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.50, a 72.53% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.82, a 180.00% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $0.65, a 55.78% decline year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.55, a 46.55% decline from fiscal 2024.
- Rein Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.90, a 147.86% increase from fiscal 2023.
- Rein Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.17, a 87.38% decline from fiscal 2022.
- Rein Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $9.27, a 613.08% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.17 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $1.55 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $1.55 10-Q · filed 2025-11-14 | |||
| 2024-12-31 | $2.90 10-K · filed 2025-04-07 | |||
| 2024-09-30 | $3.09 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $3.12 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $4.72 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | $1.17 10-K · filed 2024-04-15 | |||
| 2022-12-31 | $9.27 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $0.46 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $0.46 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $0.50 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $1.30 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $1.30 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $1.30 10-Q · filed 2021-08-11 | |||
| 2021-03-31 | $1.82 10-Q · filed 2021-05-11 | |||
| 2020-12-31 | $0.76 10-K · filed 2021-03-24 | |||
| 2020-09-30 | $0.72 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $0.72 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | $0.65 10-Q · filed 2020-05-11 | |||
| 2019-12-31 | $1.63 10-K · filed 2020-03-30 | |||
| 2019-09-30 | $1.63 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $1.63 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $1.47 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $4.16 10-K · filed 2019-03-29 | |||
| 2018-09-30 | $5.34 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $7.01 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $9.02 10-Q · filed 2018-05-09 | |||
| 2017-12-31 | $10.49 10-K · filed 2018-04-02 | |||
| 2017-09-30 | $10.50 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $8.08 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |